Results for 'RB'
Forbes Books Press Release Official
New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures
Voices of Oncology, Cancer cures, Oncology Voice Network, Kirk V. Shepard, Ramin Farhood, Forbes Books, Cancer treatment innovation, Oncology collaboration, Patient engagement in oncology, Precision medicine cancer
Voices of Oncology: Fostering a Collaborative Community of Experts to Accelerate Cancer Cures is a book by Kirk V. Shepard, M.D., and Ramin Farhood, PharmD, M.B.A., featuring insights from 33 contributors in the oncology field. It is available on platforms like Amazon and Barne…
Sep 9th • 5 mins read
Paulo J. Oliveira, Ana M. Urbano
“Oncometabolism: The switchboard of cancer: An editorial”
Otto Warburg, biochemist, FDA, FDG-PET, MRS, Oncometabolism
Otto Warburg's discovery in the 1920s highlighted a unique bioenergetic phenotype in tumor cells, emphasizing their reliance on lactic acid fermentation, which spurred the field of oncometabolism. Oncometabolism has led to advancements like FDG-PET imaging for cancer diagnosis and staging,…
Feb 1st • 1 min read
Carrie Printz
First person profile: William Sellers, MD
William Sellers, Dana Farber Cancer Institute, Harvard, melanoma
Dr. Sellers is a prominent figure in cancer research, associated with the Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute, and Harvard Medical School. He has contributed significantly to cancer genomics, particularly in identifying EGFR mutations in lung cancer a…
Nov 6th • 2 mins read
Siddharth Agrawal, Nidhi Bansal
Advances and Challenges in Pediatric and Childhood Cancers
CNS, central nervous system, ES, Ewing sarcoma, MB, medulloblastoma, PTSD, post traumatic stress disorder, RB, retinoblastoma
Pediatric cancers, while uncommon compared to adult cancers, include leukemia, CNS tumors, lymphoma, Wilms' tumor, and retinoblastoma. Challenges in pediatric cancer treatment encompass late diagnosis, varied immune responses, preserving fertility, minimizing late effects, and considering lo…
Jun 27th • 2 mins read
Michael Pietrack
Leading From the Front: 3 Leadership Lessons From Mark Cuban
Businessman and entrepreneur Mark Cuban recently discussed leadership with Leadership Lab columnist Michael Pietrack. The three lessons that came out of that conversation start with one word: caring.
Dec 17th • 6 mins read
Michael Pietrack
Leadership Lab: 5 Ways Biopharma Execs Can Restore Trust, Retain Talent After Layoffs
In the latest installment of his column, Kaye/Bassman’s Michael Pietrack shares five ways leaders can help their teams after a layoff, from acknowledging emotions to reestablishing culture.
Jun 25th • 4 mins read
Michael Pietrack
The Four Employment Agreement Questions Every Pharma Executive Must Ask
opinion, career advice, leaderhsip, legal
Clarity on employment terms is essential to protect careers. In this column, Kaye/Bassman’s Michael Pietrack speaks to employment attorney Howard Matalon, JD, partner at OlenderFeldman, on how to evaluate the fine print of an employment agreement.
Dec 18th • 6 mins read
Tom Caravela
Interview Differentiator-Be a Story Teller
interview preparation, effective interviewing, behavioral interview questions, storytelling in interviews, successful interview techniques
When you search Google for the words “Interview Preparation,” you will come up with approximately 756,000,000 results. While I am sure you can find an abundance of valuable information, it is very difficult to navigate through all of the content available on the Internet to determine wha…
Mar 22nd • 1 min read
Tom Caravela
12 Interview Techniques to Help Land Your Next Job
interview preparation, job interview tips, business etiquette, salary negotiation, follow-up after interview
Your next career move could very well be one interview away. Be sure to take every measure to prepare yourself and make the most of the opportunity. According to a recent Simply Hired survey of over 850 Managers, an overwhelming 89% said that “showing lack of preparation” will affect the…
May 12th • 1 min read
Tom Caravela
Job Search Checklist for Aspiring Medical Science Liaisons
Medical Science Liaison, MSL role, MSL career tips, Pharmaceutical industry jobs, Break into MSL career
Tips to Help Break into Your First MSL Role The Medical Science Liaison (MSL) role, has become one of the most sought-after career paths in the Pharmaceutical and Biotech industry. What does it take to land a role as a Medical Science Liaison? As an MSL Recruiter, this is a question that I am…
May 17th • 2 mins read
Tom Caravela
10 Ways to Make an Impact on a Phone Interview
phone interview tips, importance of phone screen, phone interview preparation, how to express interest in job, phone interview strategies
The phone interview, sometimes referred to by Hiring Managers and Talent Acquisition teams as the “phone screen,” is most often the first step in the interview process. While most job seekers are familiar with this concept and first step, some think of it simply as a formality or a way t…
Apr 9th • 1 min read
Tom Caravela
INTENTION: The Key to Achieving Your Goals
digital marketing, search engine optimization, content strategy, keyword research, online visibility
New Years resolutions and goals always seem to follow the same path with the same result. Start…no finish. Beginning…no end. I feel like way too many people make resolutions only to break them a few weeks later. I want to share a strategy that WORKS. Not only will it help you stick to …
Jan 21st • 1 min read
Bridget Rasmusson
Positioning Yourself to Become an MSL in 2022
MSL role, clinical background, academic background, research background, industry, MSL Society, conference, scientific expert, therapeutic expertise, pharma companies
After attending the MSL Society’s 9th annual conference in Vegas Last week, I have taken some time to reflect on inquiries our team received about how to effectively step into the MSL role from a clinical, academic, or research background. Industry is a tough nut to crack, but it is absolutely…
Dec 21st • 10 mins read
J. Remon, R. García-Campelo, E. de Álava, R. Vera, J. L. Rodríguez-Peralto, Á. Rodríguez-Lescure, B. Bellosillo, P. Garrido, F. Rojo & R. Álvarez-Alegret
Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Liquid biopsy, ctDNA, Oncology, Genomic profling, Precision medicine
The proportion of cancer patients with tumors having potentially targetable genomic alterations is increasing. Diagnosing these alterations can lead to tailored treatments and provide additional predictive information on immunotherapy efficacy. In many cases, initial tissue biopsies are ina…
Sep 26th • 17 mins read
Carrie Printz
Precision medicine for pediatric cancers lags behind that for adult cancers: Citing hurdles in clinical trial recruitment and drug development, researchers are exploring ways to close gaps
Precision Medicine, pediatrics, clinical trials
Pediatric precision oncology faces challenges due to the rarity of pediatric cancers, which limits research and funding compared to adult cancers. Dr. Katherine Janeway highlights the need for more validated pre-clinical models and pharmaceutical interest in pediatric cancers. The RACE Act, effe…
Jan 9th • 2 mins read
Mariam A. Ahmed, Chirag Patel, Nicole Drezner, Whitney Helms, Weiwei Tan, Daria Stypinski
Pivotal Considerations for Optimal Deployment of Healthy Volunteers in Oncology Drug Development
drug development, healthy, volunteers, oncology clinical trial
The content discusses the challenges and opportunities in conducting oncology clinical trials, particularly focusing on trials involving normal healthy volunteers (NHVs) and patients with cancer. There are over 5,000 ongoing oncology trials in the U.S., with low enrollment rates among adult c…
Oct 31st • 20 mins read
J. Remon, R. García-Campelo, E. de Álava, R. Vera, J. L. Rodríguez-Peralto, Á. Rodríguez-Lescure, B. Bellosillo, P. Garrido, F. Rojo & R. Álvarez-Alegret
Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Liquid biopsy, ctDNA, Oncology, Genomic profling, Precision medicine
The proportion of cancer patients with tumours that have targetable genomic alterations is increasing, which is crucial for tailored treatment and predicting immunotherapy efficacy. Initial tissue biopsies are often inadequate for precision oncology, and obtaining new tumour tissues at pr…
Sep 26th • 16 mins read
Gregory S. Calip, PharmD, MPH, PhD, Ivy P. Altomare, MD, Jenny S. Guadamuz, MSPH, PhD
Evaluating External Validity of Oncology Biosimilar Safety Studies
biologics, external validity, FDA, biosimilars, trastuzumab
Biologics are the fastest growing medication class in the US, significantly contributing to healthcare costs. The Biologics Price Competition and Innovation Act of 2009 created an abbreviated approval pathway to make biological products more accessible. A phase 3 randomized trial of SB3, a trast…
Apr 6th • 2 mins read
Francesco Cerisoli, PhD, Farzad Ali, MSc, Tamás Bereczky, MA, PhD, Natacha Bolaños, BS, Lars Bullinger, MD, Sujith Dhanasiri, MPhil, MSc, James Gallagher, PhD, Sonia García Pérez, MSc, Jan Geissler, MiBA, Yann Guillevic, DEA, Kathryn Harrison, PhD, Anasta
Building a Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in Hematology Added Value Framework for Hematologic Malignancies: A Comparative Analysis of Existing Tools
clinical value framework, hematology, Healthcare Alliance for Resourceful Medicine, Offensive Against Neoplasms in hematology, patient-reported outcomes, HARMONY, analysis
Current Value Frameworks (VFs) have limitations and do not meet HARMONY's ambitions for assessing the therapeutic/clinical value of innovative health technologies. There is a need for a cross-stakeholder agreement on the definition of "value," which varies among patients, clinicians, and payers. …
May 17th • 12 mins read
Jonathan H Seltzer MD, MBA, MA, Gary Gintant PhD, Laleh Amiri-Kordestani MD, Jack Singer MD, Luana Pesco Koplowitz MD, PhD, Javid J Moslehi MD, Ana Barac MD, PhD, Anthony F. Yu MD
Assessing cardiac safety in oncology drug development
Cardiac safety, cardiovascular, FDA, CSRC
The Cardiac Safety Research Consortium (CSRC) highlighted the importance of addressing cardiovascular (CV) adverse effects in oncology drug development during a Think Tank meeting in October 2017. With over 1,600 cancer therapies in development, the cardiovascular toxicity of cancer treatments has b…
Jun 12th • 12 mins read